A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 9, 2010, Pages 1966-1975

  Dahl, O E ^a,b   Quinlan, D J ^c   Bergqvist, D ^d   Eikelboom, J W ^e  

^a Elverum Hospital   (Norway)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Bleeding; Definition; Hip arthroplasty; Knee arthroplasty; Venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; MELAGATRAN; RIVAROXABAN; XIMELAGATRAN;

ARTICLE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; EMBASE; EPISTAXIS; GINGIVA BLEEDING; HEMATOMA; HEMATURIA; HIP ARTHROPLASTY; HIP FRACTURE; HUMAN; KNEE ARTHROPLASTY; KNEE FRACTURE; LUNG EMBOLISM; MEDLINE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROPHYLAXIS; RECTUM HEMORRHAGE; RISK FACTOR; SIDE EFFECT; SPONTANEOUS SKIN HEMATOMA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND HEMATOMA;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; CARDIOLOGY; CLINICAL TRIALS, PHASE III AS TOPIC; ENOXAPARIN; HEMORRHAGE; HUMANS; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 77956057713     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03965.x     Document Type: Article

References (26)

1. Novicoff WM, Brown TE, Cui Q, Mihalko WM, Slone HS, Saleh KJ. Mandated venous thromboembolism prophylaxis: possible adverse outcomes. J Arthroplasty 2008, 6(Suppl. 1):15-9.
2. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009, 120:2006-11.
3. Dahl OE, Borris LC, Bergqvist D, Schnack RM, Eriksson BI, Kakkar AK, Colwell CW, Caprini JA, Fletcher J, Friedman RJ, Lassen MR, Frostick SP, Sakon M, Kwong LM, Kakkar VV. Major joint replacement. A model for antithrombotic drug development: from proof-of-concept to clinical use. Int Angiol 2008, 27:60-7.
4. Hull RD, Yusen R, Bergqvist D. Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost 2009, 15:377-80.
5. Sobieraj-Teague M, Gallus AS, Eikelboom JW. The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. Curr Opin Cardiol 2008, 23:327-34.
6. Dahl OE, Bergqvist D. Current controversies in deep vein thrombosis prophylaxis after orthopaedic surgery. Curr Opin Pulm Med 2002, 8:394-7.
7. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3:692-4.
8. Points to consider on Clinical Investigation of medicinal products for prophylaxis of intra- and post-operative venous thromboembolic risk. http://www.emea.europa.eu/pdfs/human/ewp/070798en.pdf, Available at: Accessed 1 December 2009
9. Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. http://www.emea.europa.eu/pdfs/human/ewp/70798en_fin.pdf, Available at: Accessed 1 December 2009
10. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2009, 8:202-4.
11. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001, 345:1305-10.
12. Lassen MR, Bauer KA, Eriksson BI, Turpie AG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002, 359:1715-20.
13. Turpie AGG, Bauer K, Eriksson BI, Lassen MR. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002, 359:1721-6.
14. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003, 89:288-96.
15. Colwell CW, Berkowitz SD, Davidson BL, Lotke PA, Ginsberg JS, Lieberman JR, Neubauer J, McElhattan JL, Peters GR, Francis CW. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003, 1:2119-30.
16. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kälebo P, Panfilov S, Eskilson C, Andersson M. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003, 1:2490-6.
17. Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, Mouret P, Rosencher N, Andersson M, Bylock A, Jensen E, Boberg B. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009, 123:488-97.
18. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-85.
19. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-56.
20. Ginsberg JS, Davidson BL, Comp PC, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009, 24:1-9.
21. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-75.
22. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-9.
23. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-86.
24. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-80.
25. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009, 361:594-604.
26. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-15.